Intraocular siRNA Delivery Mediated by Penetratin Derivative to Silence Orthotopic Retinoblastoma Gene

Xin Gao, Xingyan Fan, Kuan Jiang, Yang Hu, Yu Liu, Weiyue Lu, Gang WeiPharmaceutics 2023 · DOI

TL;DR

This paper presents a novel non-viral gene delivery system for treating retinoblastoma, a serious eye cancer. By modifying a polyamidoamine (PAMAM) dendrimer with a cell-penetrating peptide (89WP), they created an eye-droppable formulation that effectively delivers siRNA to the back of the eye, silencing the target gene and inhibiting tumor growth in mice, all without invasive injections.

What Problem Does This Paper Address?

Inherited ocular diseases and cancers like retinoblastoma can lead to severe vision loss or blindness. Gene therapy holds immense promise for treating these conditions, but delivering therapeutic genetic material (like siRNA) to the posterior segment of the eye is a major hurdle. The eye's unique anatomy presents significant absorption barriers, making topical delivery via eye drops challenging. Current methods often rely on invasive subretinal or intravitreal injections, which are associated with discomfort, potential side effects, and poor patient compliance. This research aims to overcome these limitations by developing a safe, effective, and non-invasive method for intraocular gene delivery.

Methods

The researchers developed a ternary complex system for siRNA delivery.

  1. Primary Polyplex Formation: They first complexed siRNA with a 3rd generation polyamidoamine (PAMAM) dendrimer. This was achieved through electrostatic interactions, forming a primary polyplex (siRNA/PA). The optimal nitrogen-to-phosphorus (N/P) ratio was determined to be 2:1.
  2. Peptide Modification: A modified cell-penetrating peptide (CPP), 89WP (a derivative of penetratin), was then introduced to self-assemble with the siRNA/PA polyplex. This step was driven by hydrophobic interactions, creating the final siRNA/PA/89WP polyplex. The optimal charge ratio of 89WP to siRNA was found to be 15:1.
  3. Characterization: The resulting polyplexes were characterized for particle size and zeta potential using dynamic light scattering (DLS). Their morphology was examined using transmission electron microscopy (TEM).
  4. In Vitro Studies:
    • Cellular Uptake: The uptake efficiency of the polyplexes in retinal cells (ARPE-19 and WERI-Rb-1) was evaluated using fluorescence microscopy and flow cytometry. The role of various endocytic pathways was investigated using specific inhibitors.
  5. Gene Silencing: The ability of the polyplexes to silence a target gene (luciferase) in retinoblastoma cells (WERI-Rb-1-luci) was assessed by measuring bioluminescence.
  6. Cytotoxicity: Cell viability was evaluated using the CCK-8 assay to ensure the safety of the developed formulation.
  7. Interactions: Isothermal titration calorimetry (ITC) was used to study the binding interactions between PAMAM and siRNA, and between 89WP and the siRNA/PA polyplex.
  8. In Vivo Studies:
    • Retinal Distribution: The distribution of fluorescently labeled siRNA in the mouse retina after topical instillation was tracked over time using confocal microscopy.
  9. Gene Silencing Efficacy: The therapeutic effect was evaluated in a retinoblastoma mouse model. Mice received topical administration of the siRNA formulations, and tumor growth was monitored via bioluminescence imaging.
  10. Ocular Safety: Histological examination of the cornea was performed to assess any potential toxicity.

Datasets

Not explicitly discussed as datasets in the traditional machine learning sense. The study utilizes established cell lines (WERI-Rb-1, ARPE-19) and animal models (nude mice, ICR mice) for experimental evaluation. The WERI-Rb-1 cells were engineered to express luciferase for gene silencing studies.

Key Insights and Ideas

  • Synergistic Delivery: The combination of PAMAM dendrimers (for siRNA condensation) and the 89WP peptide (for enhanced cellular penetration) creates a powerful synergistic effect for intraocular gene delivery.
  • Non-invasive Potential: The development of an eye-droppable formulation that bypasses the need for injections is a significant step towards more patient-friendly ocular therapies.
  • Spontaneous Assembly: The ternary complex (siRNA/PA/89WP) can spontaneously assemble, simplifying the preparation process compared to multi-step layer-by-layer assembly methods.
  • Clathrin-Mediated Uptake: The polyplex primarily enters cells via clathrin-mediated endocytosis, a well-established pathway for cellular uptake. Interestingly, free 89WP appears to utilize different pathways.
  • Tumor-Specific Delivery: The formulation shows enhanced uptake and gene silencing in tumor cells (WERI-Rb-1) compared to normal retinal cells (ARPE-19), suggesting potential for targeted therapeutic action.
  • Safety Profile: The developed polyplex demonstrates good biocompatibility and lower toxicity compared to a commercial lipofection agent (Lipofectamine 2000), with no observed corneal damage in vivo.

Key Results

  • Polyplex Characterization: The siRNA/PA/89WP polyplexes had a smaller particle size (around 60 nm) and a near-neutral zeta potential compared to lipoplexes (around 200 nm and +30 mV).
  • Enhanced Cellular Uptake: The uptake efficiency of siRNA/PA/89WP15 in WERI-Rb-1 cells reached 90%, a 4.5-fold increase compared to the primary siRNA/PA polyplex.
  • Effective Gene Silencing: In vivo, the siRNA/PA/89WP formulation inhibited retinoblastoma tumor bioluminescence by approximately 4-6 times more effectively than naked siRNA or lipoplexes after 15 days of treatment.
  • Retinal Distribution: After topical instillation, siRNA-FAM/PA/89WP showed significantly higher fluorescence intensity in the retina compared to naked siRNA and was 1.5 times higher than the lipoplex at key time points.
  • Safety: No significant corneal damage was observed after 15 days of topical administration.

Limitations and Future Work

  • Free 89WP: The presence of free 89WP in the formulation, while not affecting polyplex uptake, suggests that the system might not be entirely composed of intact ternary complexes. Further investigation into the precise ratio and role of free peptide could be beneficial.
  • Long-term Efficacy and Safety: While promising, the study focused on a 15-day treatment period. Long-term efficacy and safety studies in animal models would be crucial for clinical translation.
  • Broader Ocular Diseases: The study focused on retinoblastoma. Investigating the applicability of this delivery system for other inherited ocular diseases would be a logical next step.
  • Optimization of 89WP Ratio: While 15:1 was found to be optimal for uptake, exploring a slightly wider range or different peptide modifications could potentially further enhance delivery or reduce any residual toxicity.

Summary updated

Abstract

Gene therapy brings a ray of hope for inherited ocular diseases that may cause severe vision loss and even blindness. However, due to the dynamic and static absorption barriers, it is challenging to deliver genes to the posterior segment of the eye by topical instillation. To circumvent this limitation, we developed a penetratin derivative (89WP)-modified polyamidoamine polyplex to deliver small interference RNA (siRNA) via eye drops to achieve effective gene silencing in orthotopic retinoblastoma. The polyplex could be spontaneously assembled through electrostatic and hydrophobic interactions, as demonstrated by isothermal titration calorimetry, and enter cells intactly. In vitro cellular internalization revealed that the polyplex possessed higher permeability and safety than the lipoplex composed of commercial cationic liposomes. After the polyplex was instilled in the conjunctival sac of the mice, the distribution of siRNA in the fundus oculi was significantly increased, and the bioluminescence from orthotopic retinoblastoma was effectively inhibited. In this work, an evolved cell-penetrating peptide was employed to modify the siRNA vector in a simple and effective way, and the formed polyplex interfered with intraocular protein expression successfully via noninvasive administration, which showed a promising prospect for gene therapy for inherited ocular diseases.
BibTeX
@inproceedings{gao2023intraocular,
  author = {Xin Gao and Xingyan Fan and Kuan Jiang and Yang Hu and Yu Liu and Weiyue Lu and Gang Wei},
  title = {{Intraocular siRNA Delivery Mediated by Penetratin Derivative to Silence Orthotopic Retinoblastoma Gene}},
  booktitle = {Pharmaceutics},
  year = {2023},
  doi = {10.3390/pharmaceutics15030745},
}
Figure